ReviewJournal of controlled release : official journal of the Controlled Release Society2015
Technologies for controlled, local delivery of siRNA.
Review in Journal of controlled release : official journal of the Controlled Release Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Biomimetic Cell Membrane-Coated MOFs System for Targeted Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- siRNA Delivery via Cross-Linked Gelatin Microparticles Enables Targeted Modulation of Osteogenic-Vascular Cross-Talk: An Advanced Human 3D in Vitro Test System for Therapeutic siRNA.Advanced healthcare materials · 2026Article
- Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer.International journal of nanomedicine · 2026Review
- Improvement of carboplatin chemosensitivity in lung cancer cells by siRNA-mediated downregulation of DLGAP1-AS2 expression.Scientific reports · 2025Article
- Upregulation of rate-limiting enzymes in cholesterol metabolism by PKCδ mediates endothelial apoptosis in diabetic wound healing.Cell death discovery · 2024Article
- Poly(β-aminoester) Physicochemical Properties Govern the Delivery of siRNA from Electrostatically Assembled Coatings.Biomacromolecules · 2024Article
- miR-142: A Master Regulator in Hematological Malignancies and Therapeutic Opportunities.Cells · 2023Review
- Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine.Cancers · 2022Review
- A design approach for layer-by-layer surface-mediated siRNA delivery.Acta biomaterialia · 2021Article
- Neuroprotective Effect of siRNA Entrapped in Hyaluronic Acid-Coated Lipoplexes by Intravitreal Administration.Pharmaceutics · 2021Article
- Hydrogel microspheres for spatiotemporally controlled delivery of RNA and silencing gene expression within scaffold-free tissue engineered constructs.Acta biomaterialia · 2021Article
- Lipid Lowering Drugs: Present Status and Future Developments.Current atherosclerosis reports · 2021Review
- Novel fusion peptide-mediated siRNA delivery using self-assembled nanocomplex.Journal of nanobiotechnology · 2021Article
- Injectable hydrogel with MSNs/microRNA-21-5p delivery enables both immunomodification and enhanced angiogenesis for myocardial infarction therapy in pigs.Science advances · 2021Article
- Dendriplex-Impregnated Hydrogels With Programmed Release Rate.Frontiers in chemistry · 2021Article
- In Vitro and In Vivo Assessment of PEGylated PEI for Anti-IL-8/CxCL-1 siRNA Delivery to the Lungs.Nanomaterials (Basel, Switzerland) · 2020Article
- Article
- Delivery of RNAi-Based Therapeutics for Bone Regeneration.Current osteoporosis reports · 2020Review
- Applications of RNA interference in the treatment of arthritis.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Microparticle Depots for Controlled and Sustained Release of Endosomolytic Nanoparticles.Cellular and molecular bioengineering · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The discovery of RNAi in the late 1990s unlocked a new realm of therapeutic possibilities by enabling potent and specific silencing of theoretically any desired genetic target. Better elucidation of the mechanism of action, the impact of chemical modifications that stabilize and reduce nonspecific effects of siRNA molecules, and the key design considerations for effective delivery systems has spurred progress toward developing clinically-successful siRNA therapies. A logical aim for initial siRNA translation is local therapies, as delivering siRNA directly to its site of action helps to ensure that a sufficient dose reaches the target tissue, lessens the potential for off-target side effects, and circumvents the substantial systemic delivery barriers. While locally injected or topically applied siRNA has progressed into numerous clinical trials, an enormous opportunity exists to develop sustained-release, local delivery systems that enable both spatial and temporal control of gene silencing. This review focuses on material platforms that establish both localized and controlled gene silencing, with emphasis on the systems that show most promise for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.